{"url_path":"/sec/dare/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000026-index.html","accession_number":"0001401914-26-000026","cik":"0001401914","ticker":"DARE","issuer_name":"Dare Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000026-index.html","primary_entity_key":"0001401914","primary_entity_name":"Dare Bioscience, Inc."},"word_count":373,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nIncorporated by Reference\n\nExhibit\n\nNumber\n\nDescription of Exhibit\n\nForm\n\nFile No.\n\nFiling Date\n\nExhibit No.\n\nFiled Herewith\n\n3.1\n[C](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex3-1.htm)[er](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex3-1.htm)[tificate of Designation of Series A Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex3-1.htm)\n\n8-K\n\n0001-36395\n1/29/20263.1\n\n4.1\n[F](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex4-1.htm)[orm of Investor Warrant](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex4-1.htm)\n\n8-K\n\n0001-36395\n1/29/20264.1\n\n4.2\n[Form of Agent Unit Warrant](ex41formofinvestorwarran.htm)\n\nX\n\n4.3\n[F](ex41formofinvestorwarran.htm)[orm of Agent Common Warrant](ex41formofinvestorwarran.htm)[(included in exhibit 4.2)](ex41formofinvestorwarran.htm)\n\nX\n\n10.1\n[F](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex10-1.htm)[orm of Subscription Agreement](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex10-1.htm)\n\n8-K\n\n0001-36395\n1/29/202610.1\n\n10.2\n[Grant Agreement between Daré Bioscience, Inc. and the](ex102gatesfoundationamen.htm)[Gates Foundation](ex102gatesfoundationamen.htm)[(f/k/a the Bill & Melinda Gates Foundation),](ex102gatesfoundationamen.htm)[effective as of November 11, 2024, as amended to date](ex102gatesfoundationamen.htm)\n\nX\n\n31.1\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended](exhibit311_20260331.htm)\n\nX\n\n32.1\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit321_20260331.htm)\n\n#\n\n101.INS\n\nInline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.\n\nX\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema Document\n\nX\n\n101.CAL\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\nX\n\n101.DEF\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\nX\n\n101.LAB\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\nX\n\n46\n\n101.PRE\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\nX\n\n104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\nX\n\n#Furnished herewith. This certification is being furnished solely to accompany this report pursuant to U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n47\n\nSignatures\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDaré Bioscience, Inc.\n\nDate: May 14, 2026By:/s/ Sabrina Martucci Johnson\n\nSabrina Martucci Johnson\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer and Principal Financial Officer)\n\nDate: May 14, 2026By:\n/s/ MarDee Haring-Layton\n\nMarDee Haring-Layton\n\nChief Accounting Officer\n\n(Principal Accounting Officer)\n\n48"}